Sodium phenylbutyrate slow-release

Drug Profile

Sodium phenylbutyrate slow-release

Alternative Names: 4-PB-D-alanin; 4PHENYL-BUTYRATE; LU-901; Lunaphen; Sodium phenylbutyrate - LUNAMeD AG/Paramount BioSciences LLC

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator LUNAMeD AG
  • Class Antineoplastics; Electrolytes; Phenylbutyrates; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Huntington's disease; Major depressive disorder; Primary sclerosing cholangitis; Prostate cancer; Psoriasis; Solid tumours; Tinnitus; Ulcerative colitis; Varicose veins; Vulvovaginitis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Huntington's-disease in Switzerland (PO, Tablet)
  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Major depressive disorder in Switzerland (PO, Tablet)
  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Primary-sclerosing-cholangitis in Switzerland (PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top